VYGR Stock — Voyager Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease, or PD; and multiple other diseases of the central nervous system, or CNS.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.86

Market cap

$114.9M

Cash

$132.1M

Enterprise value

-$17.2M

Balance sheet

Cash	$132.1M
Debt	$0.0M
Net cash	$132.1M
Enterprise value	-$17.2M
Basic shares	62.2M shares
Fully diluted shares	75.4M shares
Fully diluted market cap	$140.2M
Cash per share	$2.12
Quarterly burn	$25.8M
Cash runway	5.8 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

61.6M

Pre-funded warrants

0.0M

Options

10.1M

RSUs

1.9M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.7M

FDSO

75.4M

Cap table as of 2026-06-30.

Price history

Loading VYGR daily closes…

Loading price history…

Next catalyst

VY7523 · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	VY7523 Phase 1 multiple ascending dose trial of VY7523 in Alzheimer’s disease: tau PET imaging efficacy data	Phase 1	Alzheimer’s disease: tau PET imaging efficacy data	Q4 2026
Jun 12 - Jul 24 in 7 mo	VY7523	Phase 1/2	Alzheimer' s Disease (AD)	—
Jun 9 - Jul 21 in 32 mo	VY1706 Low dose	Phase 1	Alzheimer s Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

VY7523

Phase 1 · Active Modality: monoclonal antibody (IV, recombinant humanized IgG4)

Target tau

Indications

Alzheimer's disease (early AD) (Phase 1)

Catalysts

— Q4 2026

Status note Anti-tau antibody to inhibit the spread of pathological tau. Phase 1 SAD in healthy volunteers completed (acceptable safety/tolerability/immunogenicity); Phase 1 MAD in early AD patients initiated Feb 2025.

VY1706

Preclinical · Active Modality: gene therapy (TRACER capsid + vectorized siRNA)

Target tau (MAPT mRNA)

Indications

Alzheimer's disease (AD) (Preclinical)

Catalysts

— Q4 2026
— early 2027
— H2 2027

Status note Tau-silencing gene therapy: intravenously delivered TRACER capsid containing vectorized siRNA targeting tau mRNA. GLP toxicology study expected Q1 2026; IND submission anticipated Q2 2026 (after Q1 2026 Type C FDA communication); clinical trial initiation and dosing expected Q4 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VY7523
Lead indication	Alzheimer's Disease (AD)
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06874621	Phase 1/2	Active, not recruiting	Sponsor	Voyager Therapeutics	—	Alzheimer' s Disease (AD)	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT07764146	Phase 1	Recruiting	Sponsor	Voyager Therapeutics	—	Alzheimer s Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Voyager Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	427,554	-42,207	0.21%	2026-08-14
Ikarian Capital	53,063	no change	0.03%	2026-08-14
ADAR1 Capital Management	35,000	no change	0.01%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

VYGR — Voyager Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

VYGR — Voyager Therapeutics Inc.